These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39251560)

  • 1. Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib.
    Odah T; Karime C; Desai A; Picco MF; Kinnucan JA; Hashash JG; Farraye FA
    Dig Dis Sci; 2024 Oct; 69(10):3911-3919. PubMed ID: 39251560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience.
    Friedberg S; Choi D; Hunold T; Choi NK; Garcia NM; Picker EA; Cohen NA; Cohen RD; Dalal SR; Pekow J; Sakuraba A; Krugliak Cleveland N; Rubin DT
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1913-1923.e2. PubMed ID: 36898598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
    Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
    J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
    Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
    Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Effectiveness of Janus Kinase Inhibitors in the Management of Inflammatory Bowel Disease Following Liver Transplantation.
    Con D; Hilley P; Chin S; Corte C; Hafeez B; Testro A; De Cruz P; Choy M; Srinivasan A
    J Crohns Colitis; 2024 Sep; 18(9):1505-1509. PubMed ID: 38502366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort.
    Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR
    Inflamm Bowel Dis; 2024 Oct; 30(10):1707-1713. PubMed ID: 37843044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease.
    Spencer EA; Bergstein S; Dolinger M; Pittman N; Kellar A; Dunkin D; Dubinsky MC
    Inflamm Bowel Dis; 2024 Nov; 30(11):2057-2063. PubMed ID: 38134405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of JAK inhibitors in Ulcerative Colitis.
    Ferrante M; Sabino J
    J Crohns Colitis; 2020 Aug; 14(Supplement_2):S737-S745. PubMed ID: 31879750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of JAK inhibitors in Crohn's Disease.
    Rogler G
    J Crohns Colitis; 2020 Aug; 14(Supplement_2):S746-S754. PubMed ID: 31781755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
    Sandborn WJ; Ghosh S; Panes J; Schreiber S; D'Haens G; Tanida S; Siffledeen J; Enejosa J; Zhou W; Othman AA; Huang B; Higgins PDR
    Gastroenterology; 2020 Jun; 158(8):2139-2149.e14. PubMed ID: 32092309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired IFN-γ-dependent STAT3 Activation Is Associated With Dysregulation of Regulatory and Inflammatory Signaling in Monocytes of Ulcerative Colitis Patients.
    Cordes F; Lenker E; Weinhage T; Spille LJ; Bettenworth D; Varga G; Schmidt HH; Foell D
    Inflamm Bowel Dis; 2021 May; 27(6):887-901. PubMed ID: 33165509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Upadacitinib As a Second-line JAK Inhibitor in Ulcerative Colitis: A Case Series.
    Hosomi S; Nishida Y; Fujiwara Y
    Intern Med; 2024 Jul; 63(13):1882-1885. PubMed ID: 38008454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease.
    Chugh R; Braga-Neto MB; Fredrick TW; Ramos GP; Terdiman J; El-Nachef N; Loftus EV; Mahadevan U; Kane SV
    J Crohns Colitis; 2023 Apr; 17(4):504-512. PubMed ID: 36272109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.
    Sandborn WJ; Ghosh S; Panes J; Vranic I; Wang W; Niezychowski W;
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1485-93.e2. PubMed ID: 24480677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study.
    Carvalhas Gabrielli AM; Ferretti F; Monico CM; Tombetti E; Maconi G; Romeo S; Piazza O Sed N; Caprioli F; Mazzola AM; Alicante S; Bertè R; Lolli E; Scribano ML; Buscarini E; Ricci C; Carmagnola S; Ardizzone S; Cannatelli R
    Dig Dis Sci; 2024 May; 69(5):1785-1792. PubMed ID: 38530500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of upadacitinib in the achievement of clinical and endoscopic remission in hospitalized patients with ulcerative colitis.
    Nakamura N; Honzawa Y; Ohtsu T; Sano Y; Ito Y; Fukata N; Fukui T; Naganuma M
    Clin J Gastroenterol; 2024 Aug; 17(4):654-657. PubMed ID: 38683411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
    Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
    Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upadacitinib in Crohn's disease.
    Dignass A; Esters P; Flauaus C
    Expert Opin Pharmacother; 2024 Mar; 25(4):359-370. PubMed ID: 38512115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.